158 related articles for article (PubMed ID: 21520077)
1. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
2. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
4. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
5. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
McCarroll JA; Gan PP; Liu M; Kavallaris M
Cancer Res; 2010 Jun; 70(12):4995-5003. PubMed ID: 20501838
[TBL] [Abstract][Full Text] [Related]
6. Class III beta-tubulin in human development and cancer.
Katsetos CD; Herman MM; Mörk SJ
Cell Motil Cytoskeleton; 2003 Jun; 55(2):77-96. PubMed ID: 12740870
[TBL] [Abstract][Full Text] [Related]
7. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
8. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
9. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.
Andreoli M; Persico M; Kumar A; Orteca N; Kumar V; Pepe A; Mahalingam S; Alegria AE; Petrella L; Sevciunaite L; Camperchioli A; Mariani M; Di Dato A; Novellino E; Scambia G; Malhotra SV; Ferlini C; Fattorusso C
J Med Chem; 2014 Oct; 57(19):7916-32. PubMed ID: 25211704
[TBL] [Abstract][Full Text] [Related]
10. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
11. [Class III beta tubulin expression in nonsmall cell lung cancer].
Sève P; Dumontet C
Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
[TBL] [Abstract][Full Text] [Related]
12. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
13. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
14. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
15. HuR regulates beta-tubulin isotype expression in ovarian cancer.
Raspaglio G; De Maria I; Filippetti F; Martinelli E; Zannoni GF; Prislei S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
Cancer Res; 2010 Jul; 70(14):5891-900. PubMed ID: 20587520
[TBL] [Abstract][Full Text] [Related]
16. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève P; Dumontet C
Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
[TBL] [Abstract][Full Text] [Related]
17. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
18. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
19. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
20. βIII-Tubulin: biomarker of taxane resistance or drug target?
Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
